GlobalLuxRx Advances Patient-Centric Oncology Innovation with Successful Pivotal Bioequivalence Study of Enzalutamide Tablets
Riga, Latvia | August 2026 — Global Lux SIA, operating under the GloballuxRx brand, today announced the successful completion of the pivotal bioequivalence (BE) study for its differentiated Enzalutamide Film-Coated Tablets, marking a major milestone toward the planned USFDA ANDA submission in November 2026.
Enzalutamide is a leading oncology therapy for prostate cancer with significant global commercial potential. Global Lux RX has developed a patient-centric, differentiated three-strength portfolio (40 mg, 80 mg and 160 mg) using advanced formulation and particle-engineering technologies.
Key product differentiators include:
• ~40% smaller 40 mg and 80 mg tablets compared with conventional tablet designs
• 160 mg single-tablet strength, enabling the full daily dose in one tablet
• Potential reduction in daily pill burden from four 40 mg tablets to one 160 mg tablet
• Improved tablet usability addressing swallowability and long-term treatment convenience
With successful pivotal BE results and the USFDA submission targeted for November 2026 and ongoing DCP in Europe, the Enzalutamide is available for a global licensing and strategic partnering for territories outside EU and USA.
Global Lux RX is open for discussions with pharmaceutical companies and licensing partners interested in differentiated Generic opportunities using our nanotechnology development platform.
A submission-rea dy, differentiated oncology asset—combining regulatory progress, patient-centric design and commercial potential.
About Global Lux RX
Global Lux RX is a pharmaceutical development company focused on complex, differentiated and value-added generic medicines, combining formulation innovation, regulatory strategy, patient-centric design and commercial opportunities to develop partner-ready pharmaceutical assets.
Global Lux RX — Elevate Treatment. Enrich Lives.
Contact maxim.vlasenko@globalluxrx.comRiga, Latvia | August 2026 — Global Lux SIA, operating under the GloballuxRx brand, today announced the successful completion of the pivotal bioequivalence (BE) study for its differentiated Enzalutamide Film-Coated Tablets, marking a major milestone toward the planned USFDA ANDA submission in November 2026.
Enzalutamide is a leading oncology therapy for prostate cancer with significant global commercial potential. Global Lux RX has developed a patient-centric, differentiated three-strength portfolio (40 mg, 80 mg and 160 mg) using advanced formulation and particle-engineering technologies.
Key product differentiators include:
• ~40% smaller 40 mg and 80 mg tablets compared with conventional tablet designs
• 160 mg single-tablet strength, enabling the full daily dose in one tablet
• Potential reduction in daily pill burden from four 40 mg tablets to one 160 mg tablet
• Improved tablet usability addressing swallowability and long-term treatment convenience
With successful pivotal BE results and the USFDA submission targeted for November 2026 and ongoing DCP in Europe, the Enzalutamide is available for a global licensing and strategic partnering for territories outside EU and USA.
Global Lux RX is open for discussions with pharmaceutical companies and licensing partners interested in differentiated Generic opportunities using our nanotechnology development platform.
A submission-rea dy, differentiated oncology asset—combining regulatory progress, patient-centric design and commercial potential.
About Global Lux RX
Global Lux RX is a pharmaceutical development company focused on complex, differentiated and value-added generic medicines, combining formulation innovation, regulatory strategy, patient-centric design and commercial opportunities to develop partner-ready pharmaceutical assets.
Global Lux RX — Elevate Treatment. Enrich Lives.
